Biomarkers for the Prediction of Oncologic Outcomes in Non-muscle Invasive Bladder Cancer: State of Affairs and New Frontiers

Overview

Journal Transl Androl Urol

Date 2019 Jan 29

PMID 30687617

Citations 4

Authors

Francesco Soria

Shahrokh F Shariat

Affiliations

Soon will be listed here.

Citing Articles

The Feasibility and Diagnostic Adequacy of PD-L1 Expression Analysis Using the Cytoinclusion Technique in Bladder Cancer: A Prospective Single-Center Study.

Di Gianfrancesco L, Montagner I, Tormen D, Crestani A, Amodeo A, Corsi P J Clin Med. 2024; 13(14).

PMID: 39064112 PMC: 11277725. DOI: 10.3390/jcm13144072.

The Role of Checkpoint Inhibitor Expression Directly on Exfoliated Cells from Bladder Cancer: A Narrative Review.

Di Gianfrancesco L, Crestani A, Amodeo A, Corsi P, De Marchi D, Miglioranza E Diagnostics (Basel). 2023; 13(19).

PMID: 37835862 PMC: 10572290. DOI: 10.3390/diagnostics13193119.

Identification of Feature Genes of a Novel Neural Network Model for Bladder Cancer.

Zhang Y, Hua S, Jiang Q, Xie Z, Wu L, Wang X Front Genet. 2022; 13:912171.

PMID: 35719407 PMC: 9198295. DOI: 10.3389/fgene.2022.912171.

Hyperforin Induces Apoptosis Through Extrinsic/Intrinsic Pathways and Inhibits NF-ĸB-modulated Survival and Invasion Potential in Bladder Cancer.

Liu Y, Lin K, Hsieh J, Chung J, Tan Z, Hsu F In Vivo. 2019; 33(6):1865-1877.

PMID: 31662514 PMC: 6899093. DOI: 10.21873/invivo.11680.

References

Byrne R, Shariat S, Brown R, Kattan M, Morton RA J, Wheeler T . E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001; 165(5):1473-9. View

Shariat S, Kim J, Ayala G, Kho K, Wheeler T, Lerner S . Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003; 169(3):938-42. DOI: 10.1097/01.ju.0000043638.89552.ed. View

Shariat S, Kim J, Raptidis G, Ayala G, Lerner S . Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003; 61(6):1140-5. DOI: 10.1016/s0090-4295(03)00236-x. View

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

Shariat S, Ashfaq R, Karakiewicz P, Saeedi O, Sagalowsky A, Lotan Y . Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007; 109(6):1106-13. DOI: 10.1002/cncr.22521. View

Shariat S, Zlotta A, Ashfaq R, Sagalowsky A, Lotan Y . Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007; 20(4):445-59. DOI: 10.1038/modpathol.3800757. View

Bensalah K, Montorsi F, Shariat S . Challenges of cancer biomarker profiling. Eur Urol. 2007; 52(6):1601-9. DOI: 10.1016/j.eururo.2007.09.036. View

Savic S, Zlobec I, Thalmann G, Engeler D, Schmauss M, Lehmann K . The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer. 2009; 124(12):2899-904. DOI: 10.1002/ijc.24258. View

Malmstrom P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56(2):247-56. DOI: 10.1016/j.eururo.2009.04.038. View

10.

Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M . Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009; 182(5):2195-203. DOI: 10.1016/j.juro.2009.07.016. View

11.

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

12.

Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek R . Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer. 2013; 109(6):1460-6. PMC: 3776972. DOI: 10.1038/bjc.2013.372. View

13.

Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V . Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2014; 67(1):74-82. DOI: 10.1016/j.eururo.2014.06.040. View

14.

Moschini M, Sharma V, Delloglio P, Cucchiara V, Gandaglia G, Cantiello F . Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2015; 117(4):604-10. DOI: 10.1111/bju.13146. View

15.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

16.

Mbeutcha A, Shariat S, Rieken M, Rink M, Xylinas E, Seitz C . Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol. 2016; 34(11):483.e17-483.e24. DOI: 10.1016/j.urolonc.2016.05.013. View

17.

Liem E, Baard J, Cauberg E, Bus M, de Bruin D, Pes M . Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Med Oncol. 2017; 34(10):172. PMC: 5581817. DOI: 10.1007/s12032-017-1033-z. View

18.

van Kessel K, van der Keur K, Dyrskjot L, Algaba F, Welvaart N, Beukers W . Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. Clin Cancer Res. 2018; 24(7):1586-1593. DOI: 10.1158/1078-0432.CCR-17-2719. View

19.

Soria F, Gontero P . How to assess and improve health-related quality of life in bladder cancer patients. Transl Androl Urol. 2018; 7(Suppl 1):S77-S80. PMC: 5881211. DOI: 10.21037/tau.2018.02.02. View

20.

DAndrea D, Hassler M, Abufaraj M, Soria F, Ertl I, Ilijazi D . Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2018; 18(7):695-703. DOI: 10.1080/14737140.2018.1474104. View